Xiaolin Zi

Xiaolin Zi, Ph.D & M.Sc., is a tenured Professor in the Department of Urology at the University of California, Irvine (UCI), with a secondary appointment in Pharmacology. His research focuses on molecular mechanisms of urological cancers, particularly prostate and bladder malignancies, integrating epidemiology with experimental biology.

• McGill University (M.Sc., Biostatistics)
• Shanghai Medical University (Ph.D., Epidemiology)
• Case Western Reserve University (Postdoctoral Training, 1996)

Key research areas include naturally-occurring bioactive compounds (e.g., flavokawain A, lycopene) and Wnt signaling pathway modulation for cancer prevention. His work on epithelial-mesenchymal transition inhibition and tumor microenvironment manipulation has led to clinical trials like the NCI-funded phase I study on lycopene-docetaxel combinations.

Recent publications highlight epigenetic therapies (e.g., LSD1 inhibition), CRISPR-engineered cancer models, and ubiquitin-related drug targets. Funding sources include NIH, DOD, and AICR.

Scientific contributions span transgenic mouse models, humanized cell lines, and bioactive compound screening. He serves on editorial boards (PLOS ONE, Bladder, AJCEU) and national grant review panels.